When Cramer starts to see stocks moving with no promotion whatsoever, he considers it to be a gift. That is exactly what is happening right now with the semiconductor stocks. They're making major breakout moves for absolutely no reason. No news, no data points, no analyst pushes — nothing!
"That kind of spontaneous combustion is the sort of thing I used to look for at my old hedge fund because I would sense that the analysts would see the action and then find reasons to recommend these stocks once they figured out something positive to say," the "Mad Money" host said.
One stock that has been quietly rallying is Intel. Though it has been totally off the radar, Cramer still thinks it is worth considering. Intel's stock has dropped due to its connection to the secular decline in personal computers.
But that challenge is much worse for a company like HP Inc. that actually makes computers, as opposed to Intel which just makes the processors inside. More importantly, Altera, the high-end semiconductor company, will soon become part of the Intel family and give the company a less-PC oriented and a more high growth profile.
"I think Intel will be a changed story, and its stock will get 're-rated,' meaning that analysts are going to rally behind this one because it is no longer a one-trick pony," Cramer said.
Read More Cramer: Silent stocks making major breakout moves
At a certain point, Cramer began to wonder if the biotech companies with tremendous pipelines and real prospects have been punished enough. The entire group has been in the doghouse for months due to scrutiny over expensively priced meditations.
But has the group become too cheap to ignore? To get a closer look on what the charts predict for this group Cramer turned to Bob Lang, a technician who is the founder and senior strategist at ExplosiveOptions.net and a colleague of Cramer's at RealMoney.com.
Lang noticed that big money has begun flowing back into three junior growth biotechs after a prolonged period of weakness. He selected Juno Therapeutics, Isis Pharmaceuticals and Blubird Bio. All three stocks were tremendous performers in 2014, but this year they have all done next to nothing.
But Lang things all three could soon be back in business, and could be ready to resume their long-term march after taking a breather in 2015.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Medical Properties Trust, Inc: "I'm not even going to go there because I've got Ventas. I've got Deb Cafaro [CEO] with that stock so cheap, you're pulling that one."
Pure Storage: "We liked it for a trade. We made the trade, and then we went away. But it's OK down here at $13."